Filing Details
- Accession Number:
- 0001209191-19-024839
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-16 19:44:16
- Reporting Period:
- 2019-04-15
- Accepted Time:
- 2019-04-16 19:44:16
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1269021 | Portola Pharmaceuticals Inc | PTLA | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1187333 | Hollings Renton | C/O Portola Pharmaceuticals, Inc. 270 East Grand Ave. South San Francisco CA 94080 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-04-15 | 5,000 | $9.00 | 14,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-04-15 | 4,600 | $34.40 | 9,400 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-04-15 | 400 | $35.07 | 9,000 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Disposition | 2019-04-15 | 5,000 | $0.00 | 5,000 | $9.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 15,000 | 2020-04-27 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 2,826 | Indirect | Held by The Renton Family Community Property Trust |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2019.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.9700 to $34.9650, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) - (3) to this Form 4.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.0000 to $35.1800, inclusive. The reporting person undertakes to provide Portola Pharmaceuticals, Inc., any security holder of Portola Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) - (3) to this Form 4.
- The option, representing a right to purchase a total of 20,000 shares, became exercisable monthly over a two year period beginning on May 29, 2010.
Billionaire Hedge Funds
